NEWS HIGHLIGHTSMedia Articles Related to Avalide (Irbesartan / Hydrochlorothiazide)
China Pharma Holdings, Inc. Completes Clinical Trials For Candesartan Anti-Hypertension Drug
Source: Hypertension News From Medical News Today [2010.01.23]
China Pharma Holdings, Inc. ("China Pharma") (NYSE Amex: CPHI), which develops, manufactures, and markets specialty pharmaceutical products in China, announced that the Company has completed clinical trials for Candesartan, an anti-hypertension drug, and submitted the generic drug production application to the SFDA...
Beta-Blockers Effective In Combination Therapies For Hypertension
Source: Hypertension News From Medical News Today [2010.01.20]
Using beta-blockers as a second-line therapy in combination with certain anti-hypertensive drugs significantly lowers blood pressure in patients with hypertension, according to a systematic review by Cochrane Researchers. This review also goes some way to explaining the differences in the way that patients respond to beta-blockers and other classes of blood pressure lowering drugs...
SunTech Medical's Oscar 2 ABPM Used In Study Linking Vitamin D Deficiency And Hypertension
Source: Complementary Medicine / Alternative Medicine News From Medical News Today [2010.01.19]
A study led by Dr. William White and Dr. Pooja Luthra at the University of Connecticut Health Center is using the Oscar 2™, 24 hour ambulatory blood pressure monitor (ABPM) to investigate a possible link between vitamin D deficiency and hypertension...
Hypertension Drugs May Cut Alzheimer's Risk
Source: MedicineNet Dementia Specialty [2010.01.13]
Title: Hypertension Drugs May Cut Alzheimer's Risk
Category: Health News
Created: 1/13/2010 9:57:00 AM
Last Editorial Review: 1/13/2010 9:57:27 AM
Hypertension Linked To Dementia In Older Women
Source: Hypertension News From Medical News Today [2010.01.12]
Older women with hypertension are at increased risk for developing brain lesions that cause dementia later in life, according to data from the Women's Health Initiative Memory Study (WHIMS). The findings were published in the December 2009 online issue of the Journal of Clinical Hypertension...
Published Studies Related to Avalide (Irbesartan / Hydrochlorothiazide)
Raltegravir. [2008]
* Raltegravir, the first in a new class of orally administered HIV type-1 (HIV-1) integrase inhibitors, selectively inhibits the strand transfer activity of HIV-1 and its integration into human DNA, a key stage in retroviral propagation, thereby limiting viral replication and the infection of new cells...
Efficacy and safety of irbesartan/HCTZ combination therapy as initial treatment for rapid control of severe hypertension. [2006.12]
Severe hypertension is difficult to control. This prospective, randomized, double-blind, active-controlled, multicenter trial compared efficacy and safety of once-daily irbesartan/hydrochlorothiazide (HCTZ) combination therapy with irbesartan monotherapy in severe hypertension... Greater and more rapid BP reduction with irbesartan/HCTZ was achieved without additional side effects.
Irbesartan/HCTZ fixed combinations in patients of different racial/ethnic groups with uncontrolled systolic blood pressure on monotherapy. [2006.04]
The IrbesartaN/hydroChlorothiazide (HCTZ) bLood pressUre reductionS In diVErse patient populations (INCLUSIVE) trial was a multicenter, prospective, open-label, single-arm study evaluating the efficacy and safety of irbesartan/HCTZ fixed combinations in patients > or = 18 years old with uncontrolled systolic blood pressure (SBP, 140-159 mmHg; 130-159 mmHg for type-2 diabetes mellitus patients) after > or = 4 weeks of antihypertensive monotherapy...
Ambulatory blood pressure comparison of the anti-hypertensive efficacy of fixed combinations of irbesartan/hydrochlorothiazide and losartan/hydrochlorothiazide in patients with mild-to-moderate hypertension. [2005.11]
This study examined whether the greater anti-hypertensive efficacy of irbesartan monotherapy over losartan monotherapy extends to the respective fixed-dose combinations with hydrochlorothiazide (HCTZ) in patients with mild-to-moderate hypertension. Patients were treated with either irbesartan 150 mg/HCTZ 12.5 mg or losartan 50 mg/HCTZ 12.5 mg over a 4-week period.
Effect of delapril-manidipine combination vs irbesartan-hydrochlorothiazide combination on fibrinolytic function in hypertensive patients with type II diabetes mellitus. [2004.10]
The aim of this double-blind, double-dummy, parallel group study was to compare the effects of delapril-manidipine combination vs a irbesartan-hydrochlorothiazide combination on plasma tissue plasminogen activator (t-PA) and plasmogen activator inhibitor type I (PAI-l) activities in hypertensive patients with type II diabetes mellitus...
Clinical Trials Related to Avalide (Irbesartan / Hydrochlorothiazide)
Adalat ® XL® vs Diltiazem on Proteinuria and Blood Pressure in Hypertensive Diabetic Patients [Recruiting]
The study consists of a 12 week run-in period when all subjects are stabilized on a single
dose of Avalide (300 mg/12. 5 mg or 300mg/25mg dose) per day. After this 12 week run-in ends,
subjects will be randomly assigned to start the addition of either Adalat XL or Tiazac XC for
18 weeks of treatment. Subjects will have a 1 in 2 chance of receiving the study drug Adalat
XL and a 1 in 2 chance of receiving the drug Tiazac XC. An end of treatment visit will be
done 18 weeks after start of study drug. The expected duration of the study is 30 weeks. The
purpose of this study is to compare the change in proteinuria, through a urine test, while
taking study drug until high blood pressure (BP) is reduced to near normal levels in study
subjects with diabetic nephropathy and hypertension.
AMISH : Aprovel for Management of Isolated Systolic Hypertension [Completed]
To compare the antihypertensive efficacy and tolerability of irbesartan and
irbesartan-hydrochlorothiazide fixed combination therapy with amlodipine and amlodipine plus
hydrochlorothiazide in the treatment of isolated systolic hypertension.
Irbesartan/Hydrochlorothiazide to Control Elevated Blood Pressure to Target in Moderate to Severe Hypertensive Patients [Recruiting]
I SAVE - Irbesartan in Mild to Moderate Hypertensive Patients [Completed]
- To evaluate control rate of Blood Pressure ≤ 140/90 mm Hg in non-diabetic patients, and
≤ 130/80 mm Hg in diabetic patients.
- To determine percentage of patients achieving blood pressure control according to their
profile (naïve, switch, patient history, etc…) at the end of the trial.
I SELECT - Irbesartan In Hypertensive Patients With Left Ventricular Hypertrophy [Recruiting]
- To evaluate Blood Pressure (BP) reduction to the targeted values (BP ≤ 140/90 mm Hg in
non-diabetic patients, and ≤ 130/80 mm Hg in diabetic patients).
- To emphasize and to evaluate the benefit of Irbesartan in the reduction of left
ventricular mass index in hypertensive patients with left ventricular hypertrophy.
- To demonstrate safety of Irbesartan in this population.
|
